Johnson & Johnson (NYSE:JNJ) Shares Sold by Wesbanco Bank Inc.

Wesbanco Bank Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 2.2% during the 4th quarter, HoldingsChannel reports. The firm owned 149,902 shares of the company’s stock after selling 3,402 shares during the period. Johnson & Johnson accounts for 0.7% of Wesbanco Bank Inc.’s portfolio, making the stock its 29th biggest position. Wesbanco Bank Inc.’s holdings in Johnson & Johnson were worth $21,679,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson in the third quarter valued at about $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $146.76 on Friday. The company has a 50 day moving average of $147.85 and a two-hundred day moving average of $155.99. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market cap of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same quarter in the previous year, the firm posted $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on JNJ shares. Bank of America lowered their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday. Finally, Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.